Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cetuximab + IMRT feasibility study in head and neck cancer
2009-017943-32Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Mar 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Antwerp University Hospital. Primary endpoints: Feasibility of combined gemcitabine, cetuximab, and IMRT and Toxicity and safety profile. Started Mar 2010; status: completed.
02
Drugs
gemcitabinecetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-017943-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017943-32.